{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:44:28Z","timestamp":1784346268871,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A2B6005559"],"award-info":[{"award-number":["NRF-2018R1A2B6005559"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s12282-022-01359-9","type":"journal-article","created":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T14:15:55Z","timestamp":1650636955000},"page":"814-824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast"],"prefix":"10.1007","volume":"29","author":[{"given":"Ji Won","family":"Woo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Yeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yul Ri","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0299-7268","authenticated-orcid":false,"given":"So Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"1359_CR1","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.3390\/ijms20194940","volume":"20","author":"HY Loh","year":"2019","unstructured":"Loh HY, Norman BP, Lai KS, Rahman N, Alitheen NBM, Osman MA. The regulatory role of MicroRNAs in breast cancer. Int J Mol Sci. 2019;20:4940.","journal-title":"Int J Mol Sci"},{"key":"1359_CR2","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/jcp.25813","volume":"233","author":"A Bahrami","year":"2018","unstructured":"Bahrami A, Aledavood A, Anvari K, Hassanian SM, Maftouh M, Yaghobzade A, et al. The prognostic and therapeutic application of microRNAs in breast cancer: tissue and circulating microRNAs. J Cell Physiol. 2018;233:774\u201386.","journal-title":"J Cell Physiol"},{"key":"1359_CR3","doi-asserted-by":"publisher","first-page":"D155","DOI":"10.1093\/nar\/gky1141","volume":"47","author":"A Kozomara","year":"2019","unstructured":"Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019;47:D155\u201362.","journal-title":"Nucleic Acids Res"},{"key":"1359_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41416-019-0478-6","volume":"121","author":"M van Seijen","year":"2019","unstructured":"van Seijen M, Lips EH, Thompson AM, Nik-Zainal S, Futreal A, Hwang ES, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121:285\u201392.","journal-title":"Br J Cancer"},{"key":"1359_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ajpath.2018.06.025","volume":"189","author":"BN Hannafon","year":"2019","unstructured":"Hannafon BN, Ding WQ. Functional role of miRNAs in the progression of breast ductal carcinoma in situ. Am J Pathol. 2019;189:966\u201374.","journal-title":"Am J Pathol"},{"key":"1359_CR6","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ajpath.2017.11.003","volume":"188","author":"BN Hannafon","year":"2018","unstructured":"Hannafon BN, Ding WQ. miRNAs as biomarkers for predicting the progression of ductal carcinoma in situ. Am J Pathol. 2018;188:542\u20139.","journal-title":"Am J Pathol"},{"key":"1359_CR7","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1186\/1471-2407-13-512","volume":"13","author":"W Zhou","year":"2013","unstructured":"Zhou W, Jirstrom K, Amini RM, Fjallskog ML, Sollie T, Lindman H, et al. Molecular subtypes in ductal carcinoma in situ of the breast and their relation to prognosis: a population-based cohort study. BMC Cancer. 2013;13:512.","journal-title":"BMC Cancer"},{"key":"1359_CR8","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1073\/pnas.1200010109","volume":"109","author":"S Volinia","year":"2012","unstructured":"Volinia S, Galasso M, Sana ME, Wise TF, Palatini J, Huebner K, et al. Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA. Proc Natl Acad Sci USA. 2012;109:3024\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1359_CR9","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/ijc.30142","volume":"139","author":"VD Haakensen","year":"2016","unstructured":"Haakensen VD, Nygaard V, Greger L, Aure MR, Fromm B, Bukholm IR, et al. Subtype-specific micro-RNA expression signatures in breast cancer progression. Int J Cancer. 2016;139:1117\u201328.","journal-title":"Int J Cancer"},{"key":"1359_CR10","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1016\/j.celrep.2016.06.051","volume":"16","author":"R Lesurf","year":"2016","unstructured":"Lesurf R, Aure MR, Mork HH, Vitelli V, Lundgren S, Oslo Breast Cancer Research C, et al. Molecular features of subtype-specific progression from ductal carcinoma in situ to invasive breast cancer. Cell Rep. 2016;16:1166\u201379.","journal-title":"Cell Rep"},{"key":"1359_CR11","doi-asserted-by":"publisher","first-page":"4443","DOI":"10.1158\/0008-5472.CAN-11-0608","volume":"71","author":"TA Farazi","year":"2011","unstructured":"Farazi TA, Horlings HM, Ten Hoeve JJ, Mihailovic A, Halfwerk H, Morozov P, et al. MicroRNA sequence and expression analysis in breast tumors by deep sequencing. Cancer Res. 2011;71:4443\u201353.","journal-title":"Cancer Res"},{"key":"1359_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s10585-017-9868-4","volume":"35","author":"PS Soon","year":"2018","unstructured":"Soon PS, Provan PJ, Kim E, Pathmanathan N, Graham D, Clarke CL, et al. Profiling differential microRNA expression between in situ, infiltrative and lympho-vascular space invasive breast cancer: a pilot study. Clin Exp Metastasis. 2018;35:3\u201313.","journal-title":"Clin Exp Metastasis"},{"key":"1359_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3892\/or.2015.4360","volume":"35","author":"M Han","year":"2016","unstructured":"Han M, Wang F, Gu Y, Pei X, Guo G, Yu C, et al. MicroRNA-21 induces breast cancer cell invasion and migration by suppressing smad7 via EGF and TGF-beta pathways. Oncol Rep. 2016;35:73\u201380.","journal-title":"Oncol Rep"},{"key":"1359_CR14","doi-asserted-by":"publisher","first-page":"11466","DOI":"10.1074\/jbc.M117.775080","volume":"292","author":"PK Lo","year":"2017","unstructured":"Lo PK, Zhang Y, Yao Y, Wolfson B, Yu J, Han SY, et al. Tumor-associated myoepithelial cells promote the invasive progression of ductal carcinoma in situ through activation of TGFbeta signaling. J Biol Chem. 2017;292:11466\u201384.","journal-title":"J Biol Chem"},{"key":"1359_CR15","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.prp.2012.12.002","volume":"209","author":"S Li","year":"2013","unstructured":"Li S, Meng H, Zhou F, Zhai L, Zhang L, Gu F, et al. MicroRNA-132 is frequently down-regulated in ductal carcinoma in situ (DCIS) of breast and acts as a tumor suppressor by inhibiting cell proliferation. Pathol Res Pract. 2013;209:179\u201383.","journal-title":"Pathol Res Pract"},{"key":"1359_CR16","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.2147\/CMAR.S232388","volume":"12","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zeng G, Jiang Y. The emerging roles of miR-125b in cancers. Cancer Manag Res. 2020;12:1079\u201388.","journal-title":"Cancer Manag Res"},{"key":"1359_CR17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.3389\/fgene.2018.00174","volume":"9","author":"F Baldassari","year":"2018","unstructured":"Baldassari F, Zerbinati C, Galasso M, Corra F, Minotti L, Agnoletto C, et al. Screen for MicroRNA and drug interactions in breast cancer cell lines points to miR-126 as a modulator of CDK4\/6 and PIK3CA inhibitors. Front Genet. 2018;9:174.","journal-title":"Front Genet"},{"key":"1359_CR18","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1038\/onc.2013.226","volume":"33","author":"Q Li","year":"2014","unstructured":"Li Q, Yao Y, Eades G, Liu Z, Zhang Y, Zhou Q. Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene. 2014;33:2589\u2013600.","journal-title":"Oncogene"},{"key":"1359_CR19","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3390\/ncrna5040053","volume":"5","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Humphries B, Yang C, Wang Z. MiR-205 dysregulations in breast cancer: the complexity and opportunities. Noncoding RNA. 2019;5:53.","journal-title":"Noncoding RNA"},{"key":"1359_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3390\/ijms22010027","volume":"22","author":"I Plantamura","year":"2020","unstructured":"Plantamura I, Cataldo A, Cosentino G, Iorio MV. miR-205 in breast cancer: state of the art. Int J Mol Sci. 2020;22:27.","journal-title":"Int J Mol Sci"},{"key":"1359_CR21","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1002\/2211-5463.12256","volume":"7","author":"T Hasegawa","year":"2017","unstructured":"Hasegawa T, Adachi R, Iwakata H, Takeno T, Sato K, Sakamaki T. ErbB2 signaling epigenetically suppresses microRNA-205 transcription via Ras\/Raf\/MEK\/ERK pathway in breast cancer. FEBS Open Bio. 2017;7:1154\u201365.","journal-title":"FEBS Open Bio"},{"key":"1359_CR22","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.molonc.2012.03.003","volume":"6","author":"C Piovan","year":"2012","unstructured":"Piovan C, Palmieri D, Di Leva G, Braccioli L, Casalini P, Nuovo G, et al. Oncosuppressive role of p53-induced miR-205 in triple negative breast cancer. Mol Oncol. 2012;6:458\u201372.","journal-title":"Mol Oncol"},{"key":"1359_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00280-016-3208-2","volume":"79","author":"HY Zhang","year":"2017","unstructured":"Zhang HY, Liang F, Zhang JW, Wang F, Wang L, Kang XG. Effects of long noncoding RNA-ROR on tamoxifen resistance of breast cancer cells by regulating microRNA-205. Cancer Chemother Pharm. 2017;79:327\u201337.","journal-title":"Cancer Chemother Pharm"},{"key":"1359_CR24","doi-asserted-by":"publisher","first-page":"815","DOI":"10.3389\/fgene.2019.00815","volume":"10","author":"M Amorim","year":"2019","unstructured":"Amorim M, Lobo J, Fontes-Sousa M, Estevao-Pereira H, Salta S, Lopes P, et al. Predictive and prognostic value of selected MicroRNAs in luminal breast cancer. Front Genet. 2019;10:815.","journal-title":"Front Genet"},{"key":"1359_CR25","first-page":"6739","volume":"11","author":"WX Xu","year":"2019","unstructured":"Xu WX, Liu Z, Deng F, Wang DD, Li XW, Tian T, et al. MiR-145: a potential biomarker of cancer migration and invasion. Am J Transl Res. 2019;11:6739\u201353.","journal-title":"Am J Transl Res"},{"key":"1359_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.460","volume":"8","author":"W Wang","year":"2017","unstructured":"Wang W, Zhang L, Wang Y, Ding Y, Chen T, Wang Y, et al. Involvement of miR-451 in resistance to paclitaxel by regulating YWHAZ in breast cancer. Cell Death Dis. 2017;8: e3071.","journal-title":"Cell Death Dis"},{"key":"1359_CR27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12935-021-01885-0","volume":"21","author":"J Du","year":"2021","unstructured":"Du J, Zhong H, Ma B. Targeting a novel LncRNA SNHG15\/miR-451\/c-Myc signaling cascade is effective to hamper the pathogenesis of breast cancer (BC) in vitro and in vivo. Cancer Cell Int. 2021;21:186.","journal-title":"Cancer Cell Int"},{"key":"1359_CR28","doi-asserted-by":"publisher","first-page":"5974","DOI":"10.1073\/pnas.0931261100","volume":"100","author":"XJ Ma","year":"2003","unstructured":"Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci USA. 2003;100:5974\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1359_CR29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3390\/ncrna6020016","volume":"6","author":"YA Veryaskina","year":"2020","unstructured":"Veryaskina YA, Titov SE, Kometova VV, Rodionov VV, Zhimulev IF. Intratumoral heterogeneity of expression of 16 miRNA in luminal cancer of the mammary gland. Noncoding RNA. 2020;6:16.","journal-title":"Noncoding RNA"}],"updated-by":[{"DOI":"10.1007\/s12282-022-01412-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T00:00:00Z","timestamp":1667606400000}}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-022-01359-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-022-01359-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T02:52:18Z","timestamp":1675392738000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-022-01359-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["1359"],"URL":"https:\/\/doi.org\/10.1007\/s12282-022-01359-9","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s12282-022-01412-7","asserted-by":"object"}]},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"29 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2022","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12282-022-01412-7","URL":"https:\/\/doi.org\/10.1007\/s12282-022-01412-7","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the institutional review board of Seoul National University Bundang Hospital (IRB No. B-1803\/450-305). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required. Institutional review board waived the requirement for obtaining informed consent for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}